On the contrary, another in vivo study evaluating the antileukemic effect on growth and survival of CML LSCs of the DPP-4 blocker vildagliptin combined with imatinib or nilotinib in an NSG mouse model did not show a significant synergic effect. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.